• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Coartem (Artemether/Lumefantrine) Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) –

 

April 2013 

Summary View

 

WARNINGS AND PRECAUTIONS

Prolongation of the QT Interval
  • Receiving other medications that prolong the QT interval, such as class IA (quinidine, procainamide,disopyramide), or class III (amiodarone, sotalol) antiarrhythmic agents; antipsychotics (pimozide,ziprasidone); antidepressants; certain antibiotics (macrolide antibiotics, fluoroquinolone antibiotics,imidazole, and triazole antifungal agents)
Use of QT Prolonging Drugs and Other Antimalarials
  • Drugs that prolong the QT interval, including antimalarials such as quinine and quinidine, should be used cautiously following Coartem Tablets, due to the long elimination half-life of lumefantrine (3-6 days) and the potential for additive effects on the QT interval; ECG monitoring is advised if use of drugs that prolong the QT interval is medically required

  

August 2012

Summary View

 

CONTRAINDICATIONS

Strong CYP3A4 Inducers
  • Co-administration of strong inducers of CYP3A4 such as rifampin, carbamazepine, phenytoin and St. John’s wort with Coartem Tablets can result in decreased concentrations of artemether and/or lumefantrine and loss of anti-malarial efficacy.
 

WARNINGS AND PRECAUTIONS

Drug Interactions with CYP3A4
  • Drugs that have a mixed effect on CYP3A4, especially anti-retroviral drugs such as HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors, and those that have an effect on the QT interval should be used with caution in patients taking Coartem Tablets.